SCHEMBL4124245

SCHEMBL4124245

COCc1nn2c(-c3ccc(Cl)cc3)c(-c3ccccc3Cl)cnc2c1C(=O)O

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 7/20 0.43
RAB9A P51151 7/20 0.43
RXFP1 Q9HBX9 2/20 0.38
TP53 P04637 1/20 0.38
KMT2A Q03164 3/20 0.37
SMN1; SMN2 Q16637 4/20 0.36
MAPT P10636 3/20 0.36
MEN1 O00255 1/20 0.36
AHR P35869 1/20 0.36
KDM4E B2RXH2 3/20 0.36
ALDH1A1 P00352 3/20 0.36
LMNA P02545 2/20 0.36
MAPK1 P28482 1/20 0.36
EGLN1 Q9GZT9 1/20 0.35
MAP4K4 O95819 1/20 0.35
GPR119 Q8TDV5 3/20 0.35
GFER P55789 1/20 0.34
POLB P06746 1/20 0.34
USP7 Q93009 1/20 0.34
SLC6A9 P48067 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4118799 0.92 NPC1 (0.39) NPC1RAB9ARXFP1TP53KMT2A
SCHEMBL4107563 0.90 TP53 (0.40) NPC1RAB9ARXFP1TP53KMT2A
SCHEMBL4124557 0.90 RAB9A (0.41) NPC1RAB9ARXFP1TP53KMT2A
SCHEMBL4120384 0.86 CNR1 (0.43)
SCHEMBL4124278 0.83 MAP4K4 (0.46) NPC1RAB9ARXFP1KMT2ASMN1; SMN2
SCHEMBL4112770 0.83 NPC1 (0.33) NPC1RAB9AKMT2ASMN1; SMN2MAPT
SCHEMBL2085454 0.82 RXFP1 (0.38) NPC1RAB9ARXFP1TP53KMT2A
SCHEMBL4710553 0.82 CNR1 (0.33) NPC1RAB9AKMT2AMAPT
SCHEMBL2084056 0.82 RAB9A (0.38) NPC1RAB9ARXFP1TP53KMT2A
SCHEMBL4108763 0.82 SMN1; SMN2 (0.47) NPC1RAB9ARXFP1TP53KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8188097-B2 Pyrazolo[1,5-A]pyrimidine compounds MITSUBISHI TANABE PHARMA CORPORATION (JP) 2012-05-29 US disclosed
US-20090069298-A1 Pyrazolo[1,5-A]Pyrimidine Compounds TANABE SEIYAKU CO., LTD. (JP) 2009-03-12 US disclosed
EP-1945220-A1 PYRAZOLO[1,5-A]PYRIMIDINE COMPOUNDS AS CANNABINOID RECEPTOR ANTAGONISTS Mitsubishi Tanabe Pharma Corporation (JP) 2008-07-23 EP disclosed
WO-2007046548-A1 PYRAZOLO[1,5-A]PYRIMIDINE COMPOUNDS AS CANNABINOID RECEPTOR ANTAGONISTS MITSUBISHI TANABE PHARMA CORPORATION (JP) 2007-04-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090069298-A1 Pyrazolo[1,5-A]Pyrimidine Compounds RECQL, QTRT1, DPYD NPC1 3153/4885RAB9A 364/4885RXFP1 584/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.